Relay Therapeutics (RLAY) Research & Development (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Research & Development of $70.6 million for Q1 2026, down 4.4% year-over-year from $73.8 million in Q1 2025, and up 27.34% quarter-over-quarter from $55.4 million in Q4 2025.
Relay Therapeutics (RLAY) Research & Development (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Research & Development for 8 consecutive years, with $70.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 4.4% year-over-year to $70.6 million; the TTM figure through Mar 2026 stood at $258.1 million (down 16.86% YoY), while the FY2025 annual figure was $261.4 million, down 18.08% from the prior year.
- Research & Development grew to $70.6 million in Q1 2026 per RLAY's latest filing, from $55.4 million in the prior quarter.
- Across five years, Research & Development topped out at $92.0 million in Q2 2024 and bottomed at $51.7 million in Q1 2022.
- Historically, Research & Development has averaged $72.2 million across 5 years, with a median of $70.6 million in 2026.
- Annual changes were most pronounced in 2022 — Research & Development jumped 68.73% — and 2025, when it sank 30.54%.
- Relay Therapeutics' Research & Development stood at $67.3 million in 2022, then climbed by 15.19% to $77.5 million in 2023, then dropped by 12.16% to $68.1 million in 2024, then fell by 18.6% to $55.4 million in 2025, then grew by 27.34% to $70.6 million in 2026.
- Business Quant data shows RLAY's Research & Development at $70.6 million in Q1 2026, $55.4 million in Q4 2025, and $68.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | 76.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76.48 Mn |
| Mar 31, 2026 | 70.56 Mn |
| Dec 31, 2025 | 55.42 Mn |
| Sep 30, 2025 | 68.26 Mn |
| Jun 30, 2025 | 63.90 Mn |
| Mar 31, 2025 | 73.81 Mn |
| Dec 31, 2024 | 68.08 Mn |
| Sep 30, 2024 | 76.62 Mn |
| Jun 30, 2024 | 91.99 Mn |
| Mar 31, 2024 | 82.40 Mn |
| Dec 31, 2023 | 77.50 Mn |
| Sep 30, 2023 | 81.49 Mn |
| Jun 30, 2023 | 88.20 Mn |
| Mar 31, 2023 | 82.83 Mn |
| Dec 31, 2022 | 67.28 Mn |
| Sep 30, 2022 | 66.90 Mn |
| Jun 30, 2022 | 60.51 Mn |
| Mar 31, 2022 | 51.67 Mn |
| Dec 31, 2021 | 51.91 Mn |
| Sep 30, 2021 | 44.97 Mn |